The role of PIVKA II in the diagnosis of liver cancer and its mechanism in the development of liver cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000032697

Enrollment

Unknown

Registered

2020-05-07

Start date

2020-07-01

Completion date

Unknown

Last updated

2020-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

Gold Standard:pathologic diagnosis

Index test:PIVKA-II

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Adult subjects (18-80 years old); (2) A clear diagnosis of liver cancer; (3) clinically available plasma samples exceeding 3ml.

Exclusion criteria

Exclusion criteria: (1) Research subjects with missing laboratory test information; (2) Research subjects with missing key information in clinical and medical history; (3) Samples of severe hemolysis, microbial contamination, or jaundice; (4) Samples that do not meet the requirements for sample collection or processing; (5) The researcher considers the research subjects who need to terminate the trial from a medical perspective.

Design outcomes

Primary

Measure	Time frame
PIVKA-II;SEN, SPE, ACC, AUC of ROC;	—

Countries

China

Contacts

Public ContactYan Chen

yanc2015@163.com+86 13905010494

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026